United States Hyperparathyroidism Treatment Market Size, Share, Trends | Driven by Endocrine Disease Therapeutics & Surgical Innovation

Leander, Texas and Tokyo, Japan - Dec.08.2025
As per DataM intelligence research report" The Global Hyperparathyroidism Treatment Market is expected to reach at a high CAGR during the forecast period 2024-2031." Rising endocrine disorders and improved diagnostic rates are boosting the hyperparathyroidism treatment market.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/hyperparathyroidism-treatment-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, Amgen received FDA approval for a new oral calcimimetic for secondary hyperparathyroidism The drug offers fewer gastrointestinal side effects compared to current standard therapies It improves the quality of life for U.S. dialysis patients managing mineral bone disease

✅ In September 2025, a U.S. medical device firm launched a intraoperative parathyroid detection probe The probe uses autofluorescence to help surgeons locate glands during parathyroidectomy It reduces the risk of failed surgeries and complications in U.S. hospitals

✅ In July 2025, Ascendis Pharma released long-term efficacy data for its TransCon PTH therapy The data confirmed sustained normalization of calcium levels in hypoparathyroidism patients It supports the long-term use of replacement therapy in the U.S.

✅ In May 2025, The American Association of Endocrine Surgeons updated guidelines for asymptomatic primary hyperparathyroidism The guidelines recommend earlier surgical intervention to prevent bone loss and cardiovascular risk It shifts the U.S. clinical practice toward more proactive management

Japan: Recent Industry Developments

✅ In December 2025, Kyowa Kirin launched a new intravenous calcimimetic formulation for hemodialysis patients The IV formulation ensures 100% adherence during dialysis sessions in Japanese clinics It simplifies the medication burden for Japan's large dialysis population

✅ In October 2025, Olympus Corporation introduced a 4K imaging system optimized for minimally invasive parathyroid surgery The system provides enhanced visualization of neck anatomy for Japanese surgeons It supports the trend toward smaller incisions and faster recovery in Japan

✅ In August 2025, a Japanese research group published a study on the prevalence of normocalcemic hyperparathyroidism The study highlights the underdiagnosis of this subtle form of the disease in Japan It raises awareness among Japanese primary care physicians

✅ In June 2025, The Japanese Society for Dialysis Therapy updated its guidelines on mineral bone disorder (CKD-MBD) The update emphasizes strict control of PTH levels to prevent vascular calcification It aims to reduce cardiovascular mortality in Japanese dialysis patients

Hyperparathyroidism Treatment Market: Drivers
The hyperparathyroidism treatment market is expanding as awareness increases about hormonal imbalances affecting calcium levels and bone health. The condition, often caused by parathyroid gland dysfunction or chronic kidney disease, is driving demand for effective diagnostics, pharmacological therapies, and surgical interventions. Advances in PTH assay technologies, imaging systems, and minimally invasive surgery tools are improving treatment accuracy and patient outcomes. Pharmaceutical developments such as calcimimetics, vitamin D analogs, and targeted therapies are enhancing disease management. The growing elderly population and the rising prevalence of osteoporosis further fuel the market.

Healthcare providers are increasingly adopting personalized treatment approaches based on severity, underlying conditions, and biochemical markers. Technological innovations in intraoperative monitoring and robotic-assisted surgery are improving success rates for parathyroidectomy. Expansion of healthcare infrastructure, improved reimbursement policies, and greater awareness among patients support early diagnosis and intervention. With continued advancements in endocrine therapeutics and surgical technologies, the hyperparathyroidism treatment market is expected to sustain strong growth globally.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hyperparathyroidism-treatment-market?Prasad

Hyperparathyroidism Treatment Market: Major Players
OPKO Health, Pfizer, Amgen, Abbvie, Dr Reddy's, Sanofi, Teva Pharmaceuticals, Merck KGaA, ONO Pharmaceuticals, Xediton Pharmaceuticals and among others.

Segment Covered in the Hyperparathyroidism Treatment Market:
By Type
The Hyperparathyroidism Treatment market is segmented into secondary hyperparathyroidism 65% and primary hyperparathyroidism 35%, with secondary hyperparathyroidism dominating due to higher prevalence among patients with chronic kidney disease. Primary hyperparathyroidism represents a smaller but clinically significant segment. Both types require long-term management and monitoring to prevent complications. Growing awareness and early diagnosis are driving treatment adoption globally.

By Drug Type
Drug types include calcimimetics 45%, hormone replacement therapy 20%, bisphosphonates 15%, and others 20%, with calcimimetics dominating due to effectiveness in controlling parathyroid hormone levels and reducing surgical intervention. Hormone replacement therapy and bisphosphonates support bone health and symptom management. Other medications include emerging and adjunctive therapies. Continuous R&D and new drug approvals are expanding treatment options.

By Route of Administration
By route of administration, the market is divided into oral 70% and parenteral 30%, with oral administration dominating due to convenience, patient compliance, and wide availability of calcimimetics and other oral medications. Parenteral administration is used for specific therapies and hospital-based treatments. Both routes are critical for long-term disease management. Increasing awareness and adherence programs support sustained adoption.

By Distribution Channel
Distribution channels include hospital pharmacies 50%, retail pharmacies 35%, and online pharmacies 15%, with hospital pharmacies leading due to physician prescriptions and chronic disease management programs. Retail pharmacies provide convenient access for repeat prescriptions. Online pharmacies are growing with digital health adoption and home delivery models. Expanding pharmacy networks enhance treatment availability across regions.

Regional Analysis
North America - 40% Share
North America leads the Hyperparathyroidism Treatment market with 40% share due to high prevalence of secondary hyperparathyroidism, advanced healthcare infrastructure, and strong adoption of calcimimetics. The U.S. dominates regional revenue with established treatment protocols and insurance coverage. Canada contributes steadily through specialized treatment centers. Awareness programs and early diagnosis initiatives support continued growth.

Europe - 30% Share
Europe holds 30% share supported by advanced healthcare systems, regulatory support, and increasing patient awareness in Germany, France, and the UK. Secondary hyperparathyroidism is the major disease segment. Calcimimetics and hormone replacement therapy are widely adopted. Hospital and retail pharmacy networks ensure broad distribution, driving regional growth.

South America - 8% Share
South America accounts for 8% share with growth driven by increasing awareness, improving healthcare access, and adoption of calcimimetics in Brazil and Argentina. Secondary hyperparathyroidism remains the leading segment. Hospital pharmacies are the primary distribution channel. Government initiatives and expanding healthcare infrastructure support incremental adoption.

Asia Pacific - 15% Share
Asia Pacific holds 15% share driven by rising chronic kidney disease prevalence, improving healthcare infrastructure, and increasing awareness in China, India, and Japan. Secondary hyperparathyroidism dominates treatment demand. Oral administration and hospital pharmacies are widely adopted. Emerging markets are gradually increasing access to advanced therapies.

Middle East - 4% Share
The Middle East records 4% share with growth fueled by increasing awareness, hospital-based treatment adoption, and expanding pharmacy networks in Gulf countries. Secondary hyperparathyroidism is the primary disease segment. Calcimimetics are the leading drug type. Initiatives to improve chronic disease management support steady market growth.

Africa - 3% Share
Africa holds 3% share due to limited healthcare infrastructure, low treatment access, and awareness constraints in South Africa, Egypt, and Nigeria. Secondary hyperparathyroidism remains the primary focus. Hospital pharmacies dominate distribution. Gradual adoption of oral therapies and awareness programs are expected to support market growth over time.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=hyperparathyroidism-treatment-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.